Chemogenetic Tools and their Use in Studies of Neuropsychiatric Disorders

被引:0
|
作者
Neroldova, Marketa [1 ]
Stuchlik, Ales [1 ]
机构
[1] Czech Acad Sci, Lab Neurophysiol Memory, Inst Physiol, Prague, Czech Republic
关键词
Chemogenetics; DREADDs; PSAMs; Neuropsychiatric disorders; ALLOTHETIC PLACE AVOIDANCE; CHEMICAL-GENETIC APPROACH; VENTRAL TEGMENTAL AREA; DOPAMINE NEURONS; NUCLEOTIDE SPECIFICITY; RECEPTOR ANTAGONIST; NUCLEUS-ACCUMBENS; IN-VITRO; ACTIVATION; MICE;
D O I
10.33549/physiolres.935401
中图分类号
Q4 [生理学];
学科分类号
071003 ;
摘要
Chemogenetics is a newly developed set of tools that allow for selective manipulation of cell activity. They consist of a receptor mutated irresponsive to endogenous ligands and a synthetic ligand that does not interact with the wild-type receptors. Many different types of these receptors and their respective ligands for inhibiting or excitating neuronal subpopulations were designed in the past few decades. It has been mainly the G-protein coupled receptors (GPCRs) selectively responding to clozapine-N-oxide (CNO), namely Designer Receptors Exclusively Activated by Designer Drugs (DREADDs), that have been employed in research. Chemogenetics offers great possibilities since the activity of the receptors is reversible, inducible on demand by the ligand, and non-invasive. Also, specific groups or types of neurons can be selectively manipulated thanks to the delivery by viral vectors. The effect of the chemogenetic receptors on neurons lasts longer, and even chronic activation can be achieved. That can be useful for behavioral testing. The great advantage of chemogenetic tools is especially apparent in research on brain diseases since they can manipulate whole neuronal circuits and connections between different brain areas. Many psychiatric or other brain diseases revolve around the dysfunction of specific brain networks. Therefore, chemogenetics presents a powerful tool for investigating the underlying mechanisms causing the disease and revealing the link between the circuit dysfunction and the behavioral or cognitive symptoms observed in patients. It could also contribute to the development of more effective treatments.
引用
收藏
页码:S449 / S470
页数:22
相关论文
共 50 条
  • [1] The benefits of microarrays as tools for studying neuropsychiatric disorders
    Grünblatt, E
    DRUGS OF TODAY, 2004, 40 (02) : 147 - 156
  • [2] Metabolomics in Neuropsychiatric Disorders Powerful Translational Tools
    Kaddurah-Daouk, Rima
    BIOLOGICAL PSYCHIATRY, 2014, 75 (09) : 167S - 167S
  • [3] Gene Therapy for Neuropsychiatric Disorders: Potential Targets and Tools
    Shahcheraghi, Seyed H.
    Ayatollahi, Jamshid
    Lotfi, Marzieh
    Aljabali, Alaa A. A.
    Al-Zoubi, Mazhar S.
    Panda, Pritam K.
    Mishra, Vijay
    Satija, Saurabh
    Charbe, Nitin B.
    Serrano-Aroca, Angel
    Bahar, Bojlul
    Takayama, Kazuo
    Goyal, Rohit
    Bhatia, Amit
    Almutary, Abdulmajeed G.
    Alnuqaydan, Abdullah M.
    Mishra, Yachana
    Negi, Poonam
    Courtney, Aaron
    McCarron, Paul A.
    Bakshi, Hamid A.
    Tambuwala, Murtaza M.
    CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2023, 22 (01) : 51 - 65
  • [4] Genetics and epigenetics as tools to inform the pathophysiology of neuropsychiatric disorders
    Fries, Gabriel Rodrigo
    BRAZILIAN JOURNAL OF PSYCHIATRY, 2019, 41 (01) : 5 - 6
  • [5] Use of peptides combine with nanotechnology and molecular imaging - new tools for diagnosis and treatment of neuropsychiatric disorders
    Malavolta, Luciana
    Cabral, Francisco Romero
    Fernel, Lionel
    Conterras, Gamarra
    Ringheim, Anna Maria
    Bressan, Rodrigo Affonseca
    REVISTA BRASILEIRA DE PSIQUIATRIA, 2009, 31 (04) : 300 - 302
  • [6] Neuropharmacological studies with SPECT in neuropsychiatric disorders
    Heinz, A
    Jones, DW
    Raedler, T
    Coppola, R
    Knable, MB
    Weinberger, DR
    NUCLEAR MEDICINE AND BIOLOGY, 2000, 27 (07) : 677 - 682
  • [7] NEUROCHEMICAL STUDIES IN CHILDHOOD NEUROPSYCHIATRIC DISORDERS
    ANDERSON, GM
    LECKMAN, JF
    RIDDLE, MA
    SHAYWITZ, BA
    COHEN, DJ
    INTERNATIONAL JOURNAL OF NEUROSCIENCE, 1986, 31 (1-4) : 245 - 245
  • [8] CSF-studies in neuropsychiatric disorders
    Raedler, Thomas J.
    Wiedemann, Klaus
    NEUROENDOCRINOLOGY LETTERS, 2006, 27 (03) : 297 - 305
  • [9] The use of microarrays to characterize neuropsychiatric disorders: Postmortem studies of substance abuse and schizophrenia
    Lehrmann, E
    Hyde, TM
    Vawter, MP
    Becker, KG
    Kleinman, JE
    Freed, WJ
    CURRENT MOLECULAR MEDICINE, 2003, 3 (05) : 437 - 446
  • [10] Genetic studies of neuropsychiatric disorders in Costa Rica:: a model for the use of isolated populations
    Mathews, CA
    Reus, VI
    Bejarano, J
    Escamilla, MA
    Fournier, E
    Herrera, LD
    Lowe, TL
    McInnes, LA
    Molina, J
    Ophoff, RA
    Raventos, H
    Sandkuijl, LA
    Service, SK
    Spesny, M
    León, PE
    Freimer, NB
    PSYCHIATRIC GENETICS, 2004, 14 (01) : 13 - 23